| Radiation Medicine Program - Research Bites
|
|
|
|
Your source for the latest in RMP research
|
| I am excited to introduce the inaugural issue of RMP Research Bites. In line with our Year-3 Strategic Initiatives, this newsletter is part of our efforts to enhance research communication and extend our research impact both internally and externally. I hope you enjoy it! Please let us know if there are any topics you would like to see covered in future issues. – Michael Milosevic, RMP Director of Research
|
|
|
Radiomics is one of six strategic research areas within RMP to accelerate the availability of Adaptive Radiation Oncology for every patient. RMP aims to establish a pipeline for radiomics research, capitalizing on our expertise in clinical oncology, image analysis and artificial intelligence. Complimentary multidisciplinary teams have laid the groundwork to support the establishment of a robust, comprehensive Radiomics Research Program within RMP. Recent highlights include:
- Establishment of the Radiomics for Radiotherapy Research (R3) Consortium and biweekly RMP Radiomics Working Group meetings, led by Benjamin Haibe-Kains
- Use of the MIRA platform (developed by Tony Tadic & Nathan Becker) as a research engine for the R3 Consortium
- 3 publications in 2018 utilizing head & neck cancer imaging data and clinical outcomes from the Anthology of Outcomes (PMIDs: 29506884, 30416044, 29451412)
- Establishment of an EVOQ radiomics pipeline, led by Tom Purdie & Chris McIntosh
The RMP Radiomics Working Group is currently working to:
- Develop a shared repository on HPC4Health with access to GPUs for deep learning
- Implement the Radiomics Wiki, a platform that will facilitate collaborations and document pipelines, imaging datasets, and new deep learning approaches
For more information about RMP radiomics research, contact: Benjamin Haibe-Kains, Scott Bratman, Tom Purdie, Michael Milosevic.
Back to top
|
|
|
|
|
Scott Bratman
MD, PhD, FRCPC
Radiation Oncologist - Clinician Scientist, Princess Margaret Cancer Centre
Scientist, Princess Margaret Cancer Research Institute
|
|
Scott Bratman’s research focuses on uncovering novel molecular biomarkers for earlier diagnosis, risk stratification and treatment individualization for head and neck cancer. Circulating tumour DNA (ctDNA) are DNA fragments that have been shed into circulation by tumour cells, and can potentially be used for cancer assessment since they may carry the same genetic alterations as the primary tumour. Scott and his colleagues have developed CAPP-Seq - a cutting-edge liquid biopsy technology that allows cancer to be detected and monitored with a simple blood test. The technology has been patented and commercialized by Roche Molecular Diagnostics, and holds the potential for millions of people to have their cancer detected earlier. In 2018, Scott’s laboratory contributed to a groundbreaking study that revealed that tissue-specific markers in circulating blood plasma may extend beyond cancer detection to the screening of many common human diseases. In addition, he is part of a multidisciplinary team that has recently been awarded a $1.2M grant to develop blood tests that screen for pre-term births, currently the leading cause of death for Canadian children. To date, Scott's research has resulted in >60 publications, 30 major research grants supported by over $11M of funding, and 4 patent filings.
Back to top
|
|
|
|
|
|
|
|
Hosni et al. report rates and risk factors of early recurrence and predictors of outcomes after salvage therapy with higher dose, planned postoperative radiation therapy (PORT) with or without concurrent chemotherapy in oral squamous cell carcinoma patients.
|
|
|
|
Glicksman et al. present long-term follow-up toxicity and oncologic outcomes of a phase I pilot study which assesses the role of short-course pre-operative radiotherapy (PreORT) for men with unfavourable intermediate- and high-risk localized prostate cancer.
|
|
-
Cho YB, Alasti H, Kong V, Catton C, Berlin A, Chung P, Bayley A, Jaffray DA. Impact of high dose volumetric CT on PTV margin reduction in VMAT prostate radiotherapy. Phys Med Biol. 2019 Feb 7.
-
Giuliani M, Papadakos J, Broadhurst M, Jones J, McQuestion M, Le LW, Beck L, Waldron J, Ringash J. The prevalence and determinants of return to work in head and neck cancer survivors. Support Care Cancer. 2019 Feb;27(2):539-546.
- Hall SF, Griffiths RJ, O'Sullivan B, Liu FF. The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. Head Neck. 2019 Feb 4.
-
Kong V, Kwan M, Chen S, Chung P, Craig T, Rosewall T. Quantification of interobserver variability in image registration using cone beam CT for partial bladder radiotherapy-a comparison between lipiodol and bladder wall surface. Br J Radiol. 2019 Feb;92(1094):20180413.
- Papadakos JK, Charow RC, Papadakos CJ, Moody LJ, Giuliani ME. Evaluating cancer patient-reported outcome measures: Readability and implications for clinical use. Cancer. 2019 Jan 8.
- Piñeros M, Parkin DM, Ward K, Chokunonga E, Ervik M, Farrugia H, Gospodarowicz M, O'Sullivan B, Soerjomataram I, Swaminathan R, Znaor A, Bray F, Brierley J. Essential TNM: a registry tool to reduce gaps in cancer staging information. Lancet Oncol. 2019 Feb;20(2):e103-e111.
* Select publications with primary RMP authorship (first or last author)
Back to top
|
|
|
|
Grants
|
|
|
|
Genomics-based radiosensitization for HPV-negative squamous cell carcinoma of the aerodigestive tract. Project Grant, CIHR. PIs: Bratman S, Ailles LE, Haibe-Kains B. Co-Is: Jaffray D, Spreafico A, Tsao M, Wouters B, Xu W. $757,352 CAD.
|
|
|
|
Paediatric & adolescent radiotherapy without anaesthesia using AV distraction - are the patients moving? 2019 CAP Research Grant Competition, UHN. PI: Ritchie T. Co-Lead: Tsang D. $3,602 CAD
|
|
|
|
A universal self-calibrating in vivo real-time optical radiation dosimeter for quality assurance and quality control of radiotherapy treatment. Project Grant, CIHR. PIs: Rink A, Mermut O. Co-Is: Lewis D. $317,476 CAD.
|
|
-
DNA methylation profiling in cell-free DNA: a non-invasive method to screen for pre-term birth. CIHR Project Grant. PI: Hoffman MM. Co-Is: Bainbridge S, Bratman S, De Carvalho D, Wilson S. $1,212,525 CAD.
-
Methylome biomarker discovery and circulating tumor cell-derived xenografts by liquid biopsy in small cell lung cancer. Ontario Molecular Pathology Research Network, OICR. PI: Cabanero M. Co-I: Lok B. Collaborator(s): Bratman SV, De Carvalho, Liu G, Tsao MS. $203,050 CAD.
|
Grant Resources
|
|
